Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Safety and Efficacy of pALG in Conditioning Regimen for HLA-Matched Sibling HSCT in Patients With SAA or Hematological Malignancies ( pALG-MSDHSCT )

Safety and Efficacy of Anti-human T-cell Porcine Immunoglobulin in Conditioning Regimens for HLA Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia (SAA)/Hematological Malignancies

This study is a single-arm clinical study designed to evaluate the safety and efficacy of p-ALG in HLA sibling identical Hematopoietic stem cell transplantation( HSCT) conditioning regimens for severe aplastic anemia (SAA)/hematologic malignancies in patients diagnosed with hematologic malignancies or sSAA requiring allogeneic HSCT from our center. Graft anti-host disease (GVHD) is the most common and severe complication of allogeneic HSCT, which significantly affects survival and quality of life. Even among recipients of HLA-identical sibling HSCT (MSD-HSCT), the incidence of acute GVHD( aGVHD) and chronic GVHD (cGVHD) reaches 40-50% and 30-70%, respectively.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study was designed to explore the safety and efficacy of anti-human T cell porcine immunoglobulin p-ALG in the conditioning regimen of HLA sibling allogeneic hematopoietic stem cell transplantation for severe aplastic anemia (SAA)/hematological malignancies in 60 patients.

(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.

The enrollment time was 24 months, and patients were followed up for 24 months to evaluate long-term efficacy.

Pharmacokinetics, inflammatory cytokines and active antibodies were measured on day 0 before pALG administration and on days 3, 5, 7, 14, 21, 28 and 60 after p-ALG administration.

Routine follow-up after transplantation was performed to assess implantation and chimerism rate, immune reconstitution, infection prevention, graft versus host disease prevention, treatment-related mortality, and overall survival.

Blood routine, urine routine, liver and kidney function, clinical manifestations and ECOG score were recorded on 28± 7,60 ± 7,90 ± 7,180 ± 7,270 ± 7,360 ± 7,450 ± 7,540 ± 7,630 ± 7,720 ±7 days after transplantation; implantation rate, OS, aGVHD, cGVHD, CMV, EB virus and other infections were recorded.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

60

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300020
        • National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients with severe aplastic anemia (type I/II) or hematologic malignancies undergoing HLA-matched sibling hematopoietic stem cell transplantation.

Beskrivelse

Inclusion Criteria

  1. age: no age limit for severe aplastic anemia type I or II, patient or donor age>40 years for hematologic malignancies;
  2. gender: no gender limit;
  3. sibling identical hematopoietic stem cell transplantation;
  4. fair general status, ECOG score <2 points;
  5. no age limit for severe aplastic anemia, no gender limit; patient or donor age>40 years for hematologic malignancies.

Exclusion Criteria:

  1. uncontrolled viral, bacterial and fungal infections (disease progression during antifungal therapy);
  2. pregnant and lactating patients or patients unable to use appropriate contraception during treatment;
  3. psychiatric disorders or other medical conditions unable to comply with study treatment and monitoring requirements;
  4. known seropositive for HIV, active hepatitis B, active hepatitis C virus, or syphilis;
  5. history of tumor and treatment for any tumor within the past 3 years;
  6. Prior hematopoietic stem cell transplantation;
  7. Active heart disease, defined as one or more of the following: ① Long QTc syndrome or QTc interval>480ms;② Complete left bundle branch block, degree II or III atrioventricular block;③ History of arrhythmia requiring medication or severe clinical symptoms;④ American New York Heart Association classification ≥II; ④ Left ventricular ejection fraction less than 50%; History of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, history of clinically serious pericardial disease, or ECG evidence of acute ischemic or active conduction system abnormalities within 6 months prior to enrollment.
  8. Subjects considered unsuitable for enrollment by the investigator.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
p-ALG cohort

(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.

(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of acute graft-versus-host disease (aGVHD)
Tidsramme: within 100 days after hematopoietic stem cell infusion

aGVHD was evaluated via the modified Glucksberg criteriahematopoietic stem cell transplantation, diagnosed and graded according to standard criteria.

within 100 days after hematopoietic stem cell infusion
Incidence of chronic graft-versus-host disease (cGVHD)
Tidsramme: 5 years after hematopoietic stem cell transplantation

cGVHD was defined in accordance with the National Institutes of Health (NIH) guidelines

5 years after hematopoietic stem cell transplantation

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
1-year implantation rate
Tidsramme: 1-year

The rate of primary and secondary poor engraftment of neutrophils and platelets within 1 year

1-year
Overall survival rate
Tidsramme: 5 years after hematopoietic stem cell transplantation

All-cause mortality from hematopoietic stem cell infusion to the last follow-up

5 years after hematopoietic stem cell transplantation
Rejection (AA) or recurrence (malignant)
Tidsramme: 5 years after hematopoietic stem cell transplantation

Rejection (AA) or recurrence (malignant) from hematopoietic stem cell infusion to the last follow-up

5 years after hematopoietic stem cell transplantation
Incidence of fungal infection
Tidsramme: 2 years after hematopoietic stem cell infusion

Incidence of fungal infection from hematopoietic stem cell infusion to the last follow-up

2 years after hematopoietic stem cell infusion
Incidence of cytomegalovirus infection
Tidsramme: 2 years after hematopoietic stem cell infusion

Incidence of cytomegalovirus infection from hematopoietic stem cell infusion to the last follow-up

2 years after hematopoietic stem cell infusion
Incidence of Epstein-Barr virus infection
Tidsramme: 2 years after hematopoietic stem cell infusion

Incidence of Epstein-Barr virus infection from hematopoietic stem cell infusion to the last follow-up

2 years after hematopoietic stem cell infusion
Transplant-related mortality
Tidsramme: 5 years after hematopoietic stem cell infusion

Non-relapse/progression-related death occurring within 100 days after hematopoietic stem cell infusion

5 years after hematopoietic stem cell infusion
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last
Tidsramme: 2 years after hematopoietic stem cell infusion

Drug-related toxic and side effects from hematopoietic stem cell infusion to the last follow-up

2 years after hematopoietic stem cell infusion

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

30. november 2026

Primær færdiggørelse (Anslået)

31. august 2028

Studieafslutning (Anslået)

31. august 2028

Datoer for studieregistrering

Først indsendt

2. november 2026

Først indsendt, der opfyldte QC-kriterier

11. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IIT2026106

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .